Darunavir (Prezista, TMC114) has now been added to the interaction charts in full. Currently only interactions detailed in the Summary of Product Characteristics or Prescribing Information are referenced. Details of interactions presented at meetings will be added in the next few months.
The other PIs have been updated also to reflect changes in made in the wording or data presented in the most recent versions of their European Summaries of Product Characteristics and US Prescribing Information.
New printable versions of the PI charts are now available showing the addition of darunavir and any other changes.
